Kraj: Wielka Brytania
Język: angielski
Źródło: MHRA (Medicines & Healthcare Products Regulatory Agency)
Aspirin
Almus Pharmaceuticals Ltd
B01AC06
Aspirin
75mg
Gastro-resistant tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 02090000; GTIN: 05060057400142 05060057400135
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT ASPIRIN 75MG GASTRO-RESISTANT TABLETS READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. This medicine is available without prescription. However, you still need to use Aspirin 75mg Gastro-Resistant Tablets carefully to get the best results from it. Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist has told you. • Keep this leaflet. You may need to read it again. • Ask your pharmacist if you need more information or advice. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. • You must talk to a doctor if you do not feel better or if you feel worse after three days. WHAT IS IN THIS LEAFLET 1. What ASPIRIN 75MG GASTRO-RESISTANT TABLETS is and what it is used for 2. What you need to know before you take ASPIRIN 75MG GASTRO- RESISTANT TABLETS 3. How to take ASPIRIN 75MG GASTRO-RESISTANT TABLETS 4. Possible side effects 5. How to store ASPIRIN 75MG GASTRO-RESISTANT TABLETS 6. Contents of the pack and other information 1. WHAT ASPIRIN 75MG GASTRO-RESISTANT TABLETS IS AND WHAT IT IS USED FOR Aspirin belongs to a group of medicines called antiplatelet agents that help prevent your blood cells sticking together and forming a blood clot. Aspirin 75mg Tablets are principally used to prevent blood clots forming following a heart attack or stroke or to help prevent heart attacks and strokes in patients who have previously suffered from these conditions. They may have been prescribed for you if you have recently had by-pass surgery. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ASPIRIN 75MG GASTRO-RESISTANT TABLETS Do not take Aspirin 75mg Gastro-Resistant Tablets: • if you are allergic to aspirin or any of the other ingredients of this medicine (listed in section 6) • if you have ever had a bad reaction to aspirin or any other non- steroidal anti-inflammatory med Przeczytaj cały dokument
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Aspirin 75mg Gastro-Resistant Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains aspirin 75 mg. Also includes 17mg/tablet lactose. For the full list of excipients, see 6.1. 3 PHARMACEUTICAL FORM Gastro-resistant tablet. White, film coated, round tablet. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the secondary prevention of thrombotic cerebrovascular or cardiovascular disease and following by-pass surgery. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _For the management of cardiovascular or cerebrovascular disease_: Patients should seek the advice of a doctor before commencing therapy for the first time. The usual dosage, for long-term use, is 75-150mg once daily. In some circumstances a higher dose may be appropriate, especially in the short term, and up to 300mg a day may be used on the advice of a doctor. In general, acetylsalicylic acids should be used with caution in elderly patients who are more prone to adverse events. The usual adult dose is recommended in the absence of severe renal or hepatic insufficiency (see sections 4.3 and 4.4). Treatment should be reviewed at regular intervals._ _ _Antithrombotic action: _ 150mg at diagnosis and 75mg daily thereafter. Tablets taken at diagnosis should be chewed in order to gain rapid absorption. _Children:_ Do not give to children aged under 16 years, unless specifically indicated (e.g. for Kawasaki's disease). See section 4.4. Method of administration Aspirin 75 mg is for oral administration to adults only. Take the tablet with water, do not cut, chew or crush the tablet. Swallow whole. 4.3 CONTRAINDICATIONS • Hypersensitivity to salicylic acid compounds or prostaglandin synthetase inhibitors (e.g. certain asthma patients who may suffer an attack or faint and certain patients who may suffer from bronchospasm, rhinitis and urticaria), or to any of the excipients (see section 6.1). • Active, or history of peptic ulceration and/or gastric/intestinal haemorrha Przeczytaj cały dokument